INTRODUCTION
Dengue virus (DENV) is the most important arbovirus requiring high treatment cost. The virus also contributes to high mortality rate, particularly in tropical and subtropical countries. It has been a public-health concern for several years with an estimated 50 million infections worldwide per year, of which 250,000-500,000 cases turn to dengue haemorrhagic fever (DHF), leading to 25,000 deaths (1) . Besides, the prevalence and severity of dengue virus infection has increased in its geographic distribution over the past few decades.
Dengue virus is a member of the family Flaviviridae and genus Flavivirus. It is an enveloped particle containing a 10.7 kb single-stranded RNA genome of positive polarity (2) . Dengue virus has been divided into four serotypes: DENV1, DENV2, DENV3, and DENV4. It has been reported that certain sero-may contribute to increased disease severity (5) . DENV1-3 seemed to be responsible for several outbreaks in Brazil and the USA (6) . Each serotype of dengue virus may have a different genetic component associated with virulence but there has been no solid confirmation. Another possibility is that antibody-dependent enhancement (ADE) may be associated with severity in that primary infection induces insufficient protection and assists entry of virus into cells, resulting in higher peak viral titres (7).
As Thailand is one of the countries that reported dengue virus infections, enhancing our knowledge on viral dissemination patterns would be beneficial. In this study, we have investigated infection with various serotypes in Thai patients between 2004 and 2010. Moreover, we report the co-infection of dengue virus with information on clinical symptoms. We hope that our report on the changing pattern of dengue virus serotypes, along with co-infection, may provide important information on epidemiology, prevalence, and virulence of dengue infection.
MATERIALS AND METHODS
The protocol of the study was reviewed and approved by ethics committee of the Institutional Review Board (IRB), Faculty of Medicine, Chulalongkorn University, Thailand. We also included data from two previous reports (8, 9) . All the study subjects remained anonymous, and permission was granted by the director of the hospital.
Serum samples
Serum samples were collected from patients within 1-7 day(s) after the onset of fever. The samples were collected from patients who had fever, headache, rash, or myalgia/arthralgia-positive tour niquet test result, thrombocytopenia or plasma leakage since they were likely to be infected by dengue virus according to WHO criteria (4). We have investigated 
RNA extraction and reverse transcription
RNA was extracted from serum samples, using the Viral Nucleic Acid extraction kit (RBC bioscience, Taipei, Taiwan) according to the manufacturer's protocol. The extracted RNA was reverse-transcribed into cDNA by ImProm-II TM Reverse Transcriptase (Promega, Medison, WI). 
Semi-nested RT-PCR

Post-amplification step and sequence analysis
The PCR products were subjected to electrophoresis on a 2% agarose gel stained with ethidium bromide and visualized under UV light. The PCR products of the expected sizes were excised from the gel and purified using the gel purification kit (RBC bioscience, Taipei, Taiwan). The purified DNA was subjected to direct sequencing (1st base, Salangor, Malaysia), and the obtained nucleotide sequences were analyzed using the BLAST program available at the GenBank database. Serotypes were compared based on the relationship between genomic RNA of dengue virus and the serotype (10) .
Statistical analysis
The results were compared statistically by using chisquare (StatCalc version 6). The p value of <0.05 indicated statistically significant differences. Each serotype was determined independently. We cal- In 2004, DENV2 was 28.21% (n=11), which is quite similar to the proportion of DENV2 in 2007 (25%, n=8). DENV2 still showed lower proportion in 2008 (9.52%, n=8). In 2010, however, the percentage of DENV2 considerably increased up to 38.7% (n=12) (p<0.05), which also seemed to be predominant during this year, although there was no obviouslypredominant serotype amounting to 50% in 2010.
RESULTS
Comparative serotype analysis of dengue virus
The DENV3 proportion in 2004 was 5.13% (n=2) and then increased to 21.9 % (n=7) in 2007 and showed insignificant changes in 2008 and 2010 with 21.4% (n=18) and 29.03% (n=9) respectively. The details are shown in Fig. 1 . In this study, different serotypes of dengue virus throughout the study years have not shown significant differences in severity of illness due to the predominant serotypes. The common illnesses were fever and rash regardless of why serotype of dengue virus infected the patients. We found one patient co-infected with DENV3 and DENV4 in 2010.
Clinical presentation of patient co-infected with two dengue serotypes
In September 2010, a 3-year old female patient from a rural area in the northeast of Thailand came to the hospital and was admitted on day 5 after onset of febrile illness. Her symptoms were epitaxis, malaise, loss of appetite, nausea, and vomiting. On the day of admission, she had a high-grade fever without any signs of respiratory tract infection. Routine laboratory test showed haematocrit 33.3%, WBC 6700 mm 3 , N 23%, L 52.9%, M 17.4%, B 6.1%, atypical lymphocyte 3.9%, and decreased platelets on blood smear. She recovered and was discharged after 3 days of hospitalization. Dengue fever was diagnosed based on detectable IgG and IgM specific to dengue virus through ELISA. The diagnosis was confirmed by detection of DENV RNA with seminested multiplex RT-PCR. The results showed evidence of co-infection with two serotypes of dengue virus-DENV3 and DENV4 (Fig. 2) . The PCR results were confirmed by direct sequencing (accession number JF737997 for DENV3 and JF737996 for DENV4).
DISCUSSION
Our retrospective study has shown that the serotypes of dengue virus spreading in Thailand were fluctuating, which is indicative of the dynamics of virus population. Since 2000-2001, DENV1 seemed to be the main serotype spreading in the Pacific region, including Thailand (11) . Beginning in 2004, DENV1 showed its obvious predominance. In 2007, the main serotype was DENV4 and interestingly, in the following year (2008), the rapid displacement of DENV1 was observed. This report shows that serotype predominance can shift from one to another. This study is in agreement with another study demonstrating that DENV1 was replaced by DENV4 (12) . Some DENV serotypes, for example DENV1, may cause more severe illness. As the majority of the samples in this study were obtained from hospitalized patients, the results may not actually reflect the predominant serotype in a given year.
The antibodies specific to each serotype might be responsible for the dissemination pattern. Although primary infection provides cross-protection among dengue virus, it is not sufficient to completely protect patients from secondary infection, especially when the patient gets the second infection with a serotype different from that of the primary infection. There is also antibody-dependent enhancement (ADE) that mediates the entry of dengue virus into the host cell and can lead to a severe condition, particularly cross-reacting antibodies. Besides, the major sites of DENV replication are monocytes and macrophages, and when the immune system cross-reacts, it might mediate entry of virus into the Fc-bearing cell, and eventually increase replication of virus (13) . Dengue infection also affects T-cell function and triggers an increase in apoptosis which leads to a more severe condition (14) . Moreover, there was asymmetric competition among dengue serotypes. Upon testing DENV2 and DENV4, the results showed that the competition among DENV strains in cultured mosquito cells can cause a significant decrease in sizes of peak virus population. The respective percentage of each DENV serotype may be due to the competition among serotypes as well (3).
Co-circulation and co-infection with various dengue serotypes are common as has been reported from India and Brazil (15) . Our study has also shown co-circulation in the course of outbreaks. The difference in the ability of different serotypes of dengue virus to infect the host may also be due to genomic differences. Patients with multiple- The numbers show the size in base-pairs serotype infection may present with a more severe condition than those with single-serotype infection and has been reported to progress towards DHF (16) . However, our report has shown that such a hospitalized patient may also display more common conditions and can recover within 6 days from the onset of fever.
Conclusions
A single serotype of dengue virus may not be able to circulate in any given endemic area. The predominant DENV serotype has been continuously shifted from year to year depending on the herd immunity to DENV and competition among serotypes. Co-infection with various serotypes of dengue virus may not necessarily lead to a more severe condition or DHF/DSS.
